19702003) and periodic safety update report 1995 to 2003
from the French Regulatory authorities, was reviewed
to assess the safety proÔ¨Åle of calcium dobesilate.298
Adverse events included fever (26%), gastrointestinal disorders (12.5%), skin reactions (8.2%), arthralgia (4.3%), and
agranulocytosis (4.3%). No death